RxDoctor Payments Data

Akash Garg, MD

Internal Medicine · Pasadena, MDNPI 1033671615

Payments from drug & device makers

$2,767in general payments, 2019–2025

Across 142 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$646
  • AstraZeneca$302
  • AbbVie$292
  • GSK$235
  • Lilly USA, LLC$223
  • Boehringer Ingelheim$148
  • plus $920 from 16 others

What the payments were for

  • Food & beverage$2,767100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,767 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$112,220
Medicare patients
256
Services billed
939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$61,663
EliquisApixaban42$52,295
OzempicSemaglutide22$49,762
RybelsusSemaglutide16$41,083
XareltoRivaroxaban25$37,394
JanuviaSitagliptin Phosphate25$34,852
TrulicityDulaglutide14$28,531
FarxigaDapagliflozin Propanediol19$28,085
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$22,895
MounjaroTirzepatide16$20,560
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$15,715
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$10,879
OxycontinOxycodone Hcl13$9,551
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$3,369
Albuterol Sulfate HfaAlbuterol Sulfate93$2,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$646$90,84438 claims
Boehringer IngelheimJardiance$148$61,66340 claims
PfizerEliquis$60$52,29542 claims
Lilly USA, LLCTrulicity, Mounjaro$223$49,09130 claims
AstraZenecaFarxiga, Breztri Aerosphere$302$43,80033 claims
GSKTrelegy Ellipta$235$22,89516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Pasadena

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →